edaravone
Selected indexed studies
- Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. (Stroke, 2021) [PMID:33588596]
- Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. (Acta Neurol Belg, 2024) [PMID:38347315]
- Edaravone May Prevent Ferroptosis in ALS. (Curr Drug Targets, 2020) [PMID:32077821]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Edaravone May Prevent Ferroptosis in ALS. (2020) pubmed
- Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. (2019) pubmed
- Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. (2022) pubmed
- Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial. (2021) pubmed
- Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. (2024) pubmed
- Edaravone for the treatment of amyotrophic lateral sclerosis. (2019) pubmed
- Edaravone: A Novel Possible Drug for Cancer Treatment? (2024) pubmed
- Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2/HO-1 signaling pathway in mice. (2022) pubmed
- Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis. (2024) pubmed
- Edaravone for acute ischemic stroke - Systematic review with meta-analysis. (2022) pubmed